Clinical Handbook of Psychotropic Drugs

New in this edition:

• Antidepressants chapter includes a new section on the NMDA receptor antagonist/CYP2D6 inhibitor combination product (dextromethorphan/bupropion)
• Antipsychotics updates include revised clozapine monitoring tables which now also contain monitoring requirements for patients with or without non-benign ethnic neutropenia
• Mood Stabilisers sections on Lithium and Anticonvulsants extensively revised
• Dementia chapter includes a new section on lecanemab, a new fast-track FDA-approved treatment for Alzheimer’s disease
• Treatment of Substance Use Disorders includes revisions to buprenorphine dosing section that include a rapid micro-induction method (Bernese method) that allows treatment to start without waiting for patient to be in withdrawal
• Unapproved treatments of Psychiatric Disorders, Natural Health Products, and Pharmacogenetics chapters all substantially revised
• New formulations and trade names include: Auvelity (dextromethorphan/bupropion extended-release tablets), Invega Hafyera (paliperidone 6-monthly IM injection), Leqembi (lecanemab infusion), Subutex (buprenorphine sublingual tablets), Quviviq (daridorexant tablets)

New in this edition:

• New chapters on Prescribing Safely and Ethically to Children and Adolescents, Pharmacogenetic Information for Common Psychotropic Drugs, and Aggression Management in Children and Adolescents
• Neuroscience-based nomenclature added to Product Availability tables
• Antipsychotic-Induced Extrapyramidal Side Effect (EPSE) chapter completely revised, plus new section on monitoring scales for EPSE
• Anxiolytics section on buspirone and benzodiazepine comparison table revised
• Mood Stabilizers chapter extensively revised
• Natural Health Products comprehensively revised
• New Unapproved Treatments revised, including preliminary evidence for cannabidiol and folinic acid for autism spectrum disorder and ketamine for mood disorder
• New agents: deutetrabenazine, ethopropazine, lemborexant, lumateperone, orphenadrine, tetrabenazine, valbenazine, viloxazine
• New formulations and trade names: Austedo, Caplyta, Dayvigo, Drizalma Sprinkle, Elepsia XR, Eprontia, Evekeo ODT, Gocovri, Hetlioz LQ, Ingrezza, Invega Hafyera, Jornay PM, Loreev XR, Lybalvi, Osmolex ER, Oxtellar XR, Parsitan, Perseris, Qelbree, Qudexy XR, Secuado, Spritam, Tyrvaya, Valtoco

In addition to the spiral-bound print editions, the CHPD and the CHPD for Children and Adolescents are also available as online versions with added features that allow even quicker access to the wealth of information provided:

• Drug monographs
• Drug comparisons
• Responsive design
• Full-text search
• Auto-completion powered search function
• Browse features for generic names, trade names, indication, and interacting agents
• Hundreds of additional references
• Literature hot links for quick access to further reading

Access is available by subscription. For individual customers, subscriptions are available on a 2-year rolling basis. Access details will be e-mailed once your order has been processed (usually within minutes). If you are interested in access for institutions, please contact us via e-mail with your particular requirements. If you prefer not to subscribe online, or for any order enquiries, please contact us.

Free trial access

Get free trial access to CHPD Online and CHPD for Children & Adolescents Online for 14 days. Your trial access to each publication will be valid for 14 days from the time you redeem the code. Click here to see how it works.

If you have any questions or concerns, please don’t hesitate to contact our CHPD Online support.